Expression and characterization of recombinant humanized anti-HER2 single-chain antibody in Pichia pastoris for targeted cancer therapy

Xiaodan Cao; Haijun Yu; Chao Chen; Jia Wei; Ping Wang

doi:10.1007/s10529-015-1804-6

Expression and characterization of recombinant humanized anti-HER2 single-chain antibody in Pichia pastoris for targeted cancer therapy

Xiaodan Cao, Haijun Yu, Chao Chen, Jia Wei, Ping Wang

Bioproducts and Biosystems Engineering

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Objectives: The availability of self-targeting and low immunogenic therapeutic agents is critical to efficient cancer therapy. Therefore, the development of humanized therapeutic antibodies is particularly appealing. Results: A humanized single-chain variable fragment (scFv) antibody that can target human epidermal growth factor receptor-2 (HER2)-overexpressing cancer cells was designed and produced via expression in Pichia pastoris. The expression gave a high yield of 8 mg protein/l (with a purity of 92 %) using shake-flask cultures. Functional studies also revealed that the purified recombinant anti-HER2 scFv exhibited anti-proliferative activity and could bind efficiently to HER2-overexpressing human breast cancer cell line SKBR3. Conclusion: The recombinant scFv offers promising therapeutic and binding efficiencies that are desirable for targeted cancer therapies.

Original language	English (US)
Pages (from-to)	1347-1354
Number of pages	8
Journal	Biotechnology Letters
Volume	37
Issue number	7
DOIs	https://doi.org/10.1007/s10529-015-1804-6
State	Published - Jul 5 2015

Bibliographical note

Funding Information:
This work was supported by China Postdoctoral Science Foundation Grant (2013M540341), Key grant cultivating interdisciplinary studies of Chinese Education Ministry (WF1113014), National Natural Science Foundation of China (21303050 and 31471659), and Pujiang Talent Program of Shanghai Municipality (13PJD012).

Publisher Copyright:
© 2015, Springer Science+Business Media Dordrecht.

Keywords

Anti-HER2
Breast cancer cell line SKBR3
Cancer therapy
Heterogeneous expression
Humanized single-chain variable fragment
Pichia pastoris

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1007/s10529-015-1804-6

Cite this

@article{3e4d6550f83d4482807ac4acde64ed42,

title = "Expression and characterization of recombinant humanized anti-HER2 single-chain antibody in Pichia pastoris for targeted cancer therapy",

abstract = "Objectives: The availability of self-targeting and low immunogenic therapeutic agents is critical to efficient cancer therapy. Therefore, the development of humanized therapeutic antibodies is particularly appealing. Results: A humanized single-chain variable fragment (scFv) antibody that can target human epidermal growth factor receptor-2 (HER2)-overexpressing cancer cells was designed and produced via expression in Pichia pastoris. The expression gave a high yield of 8 mg protein/l (with a purity of 92 %) using shake-flask cultures. Functional studies also revealed that the purified recombinant anti-HER2 scFv exhibited anti-proliferative activity and could bind efficiently to HER2-overexpressing human breast cancer cell line SKBR3. Conclusion: The recombinant scFv offers promising therapeutic and binding efficiencies that are desirable for targeted cancer therapies.",

keywords = "Anti-HER2, Breast cancer cell line SKBR3, Cancer therapy, Heterogeneous expression, Humanized single-chain variable fragment, Pichia pastoris",

author = "Xiaodan Cao and Haijun Yu and Chao Chen and Jia Wei and Ping Wang",

note = "Funding Information: This work was supported by China Postdoctoral Science Foundation Grant (2013M540341), Key grant cultivating interdisciplinary studies of Chinese Education Ministry (WF1113014), National Natural Science Foundation of China (21303050 and 31471659), and Pujiang Talent Program of Shanghai Municipality (13PJD012). Publisher Copyright: {\textcopyright} 2015, Springer Science+Business Media Dordrecht.",

year = "2015",

month = jul,

day = "5",

doi = "10.1007/s10529-015-1804-6",

language = "English (US)",

volume = "37",

pages = "1347--1354",

journal = "Biotechnology Letters",

issn = "0141-5492",

publisher = "Springer Netherlands",

number = "7",

}

TY - JOUR

T1 - Expression and characterization of recombinant humanized anti-HER2 single-chain antibody in Pichia pastoris for targeted cancer therapy

AU - Cao, Xiaodan

AU - Yu, Haijun

AU - Chen, Chao

AU - Wei, Jia

AU - Wang, Ping

N1 - Funding Information: This work was supported by China Postdoctoral Science Foundation Grant (2013M540341), Key grant cultivating interdisciplinary studies of Chinese Education Ministry (WF1113014), National Natural Science Foundation of China (21303050 and 31471659), and Pujiang Talent Program of Shanghai Municipality (13PJD012). Publisher Copyright: © 2015, Springer Science+Business Media Dordrecht.

PY - 2015/7/5

Y1 - 2015/7/5

N2 - Objectives: The availability of self-targeting and low immunogenic therapeutic agents is critical to efficient cancer therapy. Therefore, the development of humanized therapeutic antibodies is particularly appealing. Results: A humanized single-chain variable fragment (scFv) antibody that can target human epidermal growth factor receptor-2 (HER2)-overexpressing cancer cells was designed and produced via expression in Pichia pastoris. The expression gave a high yield of 8 mg protein/l (with a purity of 92 %) using shake-flask cultures. Functional studies also revealed that the purified recombinant anti-HER2 scFv exhibited anti-proliferative activity and could bind efficiently to HER2-overexpressing human breast cancer cell line SKBR3. Conclusion: The recombinant scFv offers promising therapeutic and binding efficiencies that are desirable for targeted cancer therapies.

AB - Objectives: The availability of self-targeting and low immunogenic therapeutic agents is critical to efficient cancer therapy. Therefore, the development of humanized therapeutic antibodies is particularly appealing. Results: A humanized single-chain variable fragment (scFv) antibody that can target human epidermal growth factor receptor-2 (HER2)-overexpressing cancer cells was designed and produced via expression in Pichia pastoris. The expression gave a high yield of 8 mg protein/l (with a purity of 92 %) using shake-flask cultures. Functional studies also revealed that the purified recombinant anti-HER2 scFv exhibited anti-proliferative activity and could bind efficiently to HER2-overexpressing human breast cancer cell line SKBR3. Conclusion: The recombinant scFv offers promising therapeutic and binding efficiencies that are desirable for targeted cancer therapies.

KW - Anti-HER2

KW - Breast cancer cell line SKBR3

KW - Cancer therapy

KW - Heterogeneous expression

KW - Humanized single-chain variable fragment

KW - Pichia pastoris

UR - http://www.scopus.com/inward/record.url?scp=84930376886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930376886&partnerID=8YFLogxK

U2 - 10.1007/s10529-015-1804-6

DO - 10.1007/s10529-015-1804-6

M3 - Article

C2 - 25735855

AN - SCOPUS:84930376886

VL - 37

SP - 1347

EP - 1354

JO - Biotechnology Letters

JF - Biotechnology Letters

SN - 0141-5492

IS - 7

ER -

Expression and characterization of recombinant humanized anti-HER2 single-chain antibody in Pichia pastoris for targeted cancer therapy

Abstract

Bibliographical note

Keywords

UN SDGs

Access

Other files and links

Fingerprint

Cite this